In the past decade, the emergence of machine learning (ML) applications has led to
significant advances towards implementation of personalised medicine approaches for …

Background & Aims Identifying patients at high risk of immunogenicity is important when
selecting tumor necrosis factor (TNF)-α antagonists in patients with immune-mediated …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

The number of available biological therapies have doubled over the last 10 years and the
arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the …

Importance There are conflicting data on the association of antidrug antibodies with
response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid …

Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel
disease (IBD), and even fewer have been identified in the pediatric population. However, it …

Hypothesis While conventional in silico immunogenicity risk assessments focus on
measuring immunogenicity based on the potential of therapeutic proteins to be processed …

Abstract Background HLA-DQA1* 05 carriage has been associated with an increased risk of
immunogenicity in patients with immune-mediated inflammatory diseases treated with …

Biologicals are widely used therapeutic agents for rheumatologic diseases, cancers, and
other chronic inflammatory diseases. They are characterized by complex structures and …

Objective Anti-drug antibodies (ADA) to anti-tumour necrosis factor (anti-TNF) therapy drive
treatment loss of response. An association between intestinal microbial composition and …